Apologize in advance for novice question (accounting is not my forte).
Audited receivables was A$224k.
Richard states total sales for the quarter was A$535k.
So there is a difference of $311k.
We know the Biosana contract was signed at U$260k (~A$350k).
So is the $311k difference the Biosana contract or was it just additional analytics services from other customers?
If we take the un-audited earnings, it gives us $1.1M for FY18
Column 1
Column 2
Column 3
Column 4
0
Q3 CY17
Q4 CY18
Q1 CY18
Q2 CY18
1
$ 237,000
$151,000
$ 206,000
$535,000
This is similar to FY17 results which was $1.1M.
I purposely exclude the R&D grants as that is not a sustainable revenue model in my opinion.
Anyway, my question is - will the unaudited difference of $311k show up in the next quarterly?
PIQ Price at posting:
25.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)